Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG - Free Report) in a research report sent to investors on Saturday morning,Weiss Ratings reports.
TXG has been the topic of several other research reports. The Goldman Sachs Group cut their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Bank of America raised their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Finally, Morgan Stanley lowered their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $13.54.
Get Our Latest Stock Report on 10x Genomics
10x Genomics Stock Performance
TXG stock traded down $0.27 during midday trading on Friday, reaching $14.01. The company's stock had a trading volume of 1,566,109 shares, compared to its average volume of 3,022,419. The stock has a fifty day simple moving average of $12.92 and a two-hundred day simple moving average of $10.68. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.76.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter last year, the firm posted ($0.32) earnings per share. The business's revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.
Insider Activity at 10x Genomics
In related news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Orion Porfolio Solutions LLC purchased a new position in 10x Genomics during the second quarter valued at approximately $158,000. Nikko Asset Management Americas Inc. raised its position in 10x Genomics by 12.1% during the second quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company's stock valued at $69,532,000 after acquiring an additional 646,997 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in 10x Genomics by 167.9% during the second quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company's stock valued at $256,000 after acquiring an additional 13,831 shares in the last quarter. Exome Asset Management LLC purchased a new position in 10x Genomics during the second quarter valued at approximately $1,895,000. Finally, Corient Private Wealth LLC purchased a new stake in shares of 10x Genomics in the second quarter valued at approximately $597,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Further Reading
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
